Introduction {#Sec1}
============

Clinical and experimental studies have provided considerable evidence for the role of the renin-angiotensin system (RAS) in the development of hypertension and progression of renal diseases \[[@CR1], [@CR2]\]. It is now established that all components of the RAS are widely distributed in several tissues, including the kidney \[[@CR3], [@CR4]\]. The local RAS in the kidney has several pathophysiologic functions for not only regulating blood pressure but also renal cell growth and production of glomerulosclerosis, which is involved in the development of renal fibrosis \[[@CR5]--[@CR8]\]. Indeed, previous studies have shown beneficial effects of angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin II (ang II) type 1 receptor (AT1R) blocker (ARB) on various renal diseases in rats and humans, often to an extent far greater than their effect on blood pressure \[[@CR9]--[@CR11]\].

IgA nephropathy (IgAN) is now recognized to be the most common form of glomerulonephritis worldwide. It has been reported that more than 30% of cases progress to end-stage renal failure within 20 years \[[@CR12], [@CR13]\]. In pediatric IgAN, glomerular lesion is characterized by an increased number of mesangial cells (MC) and accumulation of mesangial extracellular matrix (ECM), and this pathological change is thought to be an early and active lesion for IgAN \[[@CR14]\]. It is reported that treatment with ACEi and/or ARB provides antiproteinuric and renoprotective effects in normotensive pediatric patients with IgAN, suggesting that intrarenal action of ang II may play a critical role in the progression of pediatric IgAN \[[@CR15], [@CR16]\]. Recently, a real-time polymerase chain reaction (RT-PCR) study using isolated glomeruli with IgAN revealed an increased expression of RAS components such as renin, angiotensinogen (AGT), and ACE, possibly followed by the production of ang II, an effector molecule of RAS, suggesting that the glomerular RAS activation might occur under this disease setting \[[@CR17]\]. In this study, AGT messenger ribonucleic acid (mRNA) levels were positively correlated with the mRNA expression of renin, ACE, and a fibrogenic cytokine transforming growth factor-β (TGF-β). AGT is the sole substrate for the RAS pathway, and it has been reported that AGT is present within the kidney and ang II is produced locally, independent of the circulating RAS \[[@CR18]\]. Interestingly, the increased expression of intrarenal AGT is directly involved in the disease progression in several rat models of renal injury \[[@CR19]--[@CR22]\]. However, little information is available about protein expression in an RAS cascade from AGT to ang II and the association between glomerular RAS activation and pathological changes in childhood IgAN.

Therefore, in this study, the glomerular protein expression of RAS components such as AGT, ACE, ang II, and AT1R, as well as their association with the index of glomerular injury were examined to clarify the role of the RAS cascade, especially that of AGT in glomerular lesions of pediatric IgAN. Subsequently, we investigated the amplification mechanism of glomerular AGT expression leading to an increase of glomerular RAS activity using cultured human glomerular endothelial cells (GEC).

Materials and methods {#Sec2}
=====================

Kidney tissue {#Sec3}
-------------

Renal tissues used for this study were obtained from 23 children with IgAN and eight with minor glomerular abnormalities (MGA) by biopsy. Diagnosis of renal diseases was made based on studies of tissue by light, electron, and immunofluorescence microscopy according to the classification of the World Health Organization (WHO) \[[@CR23]\]. This classification defined diffuse mesangial proliferation as \>80% of glomeruli showing moderate or severe mesangial cell proliferation, i.e. more than three cells per peripheral mesangial area, and focal mesangial proliferation as up to 80% of glomeruli showing the same changes described above. IgAN was diagnosed as a mesangial proliferative glomerulonephritis with predominant IgA deposit in the mesangium. Patients diagnosed with IgAN showed diffuse mesangial proliferation (15) or focal mesangial proliferation (8). Patients diagnosed with MGA showed normal glomerular morphology and negative immunofluorescence but had mild proteinuria or microscopic hematuria. All subjects with other disorders, including Henoch-Schönlein purpura, systemic lupus erythematosus, and chronic liver disease, were excluded. The control tissue (5) consisted of normal cortex taken from kidneys resected for localized neoplasms. Blood pressure, serum creatinine, and creatinine clearance were normal in all participants at the time of biopsy. Patients had not been previously treated with either ACEi, ARB, glucocorticosteroids, or immunosuppressive agents. The study protocol was approved by the ethics committee of the University of Tokushima Graduate School, and written informed consent was obtained from all patients and/or their parents in all cases. The clinical laboratory parameters, including age, term from onset of urinary abnormalities to renal biopsy, blood pressure, proteinuria, hematuria index, serum creatinine, and 24-h creatinine clearance were determined at the time of biopsy. Based on examination of urine samples, the severity of hematuria was classified as follows: 0, 0--5 erythrocytes/high-power field (HPF); 1+, 5--30 erythrocytes/HPF; 2+, \>30 erythrocytes/HPF; 3+, macroscopic hematuria, as previously described \[[@CR24]\]. Clinical data are presented in Table [1](#Tab1){ref-type="table"}. Table 1Clinical data of patients MGAIgANNumber823Age (years)13.1 ± 1.913.0 ± 3.1Term from onset of urinary abnormalities to renal biopsy (years)1.5 ± 1.20.9 ± 0.7Systolic/diastolic blood pressure (mmHg)112.1 ± 9.5/62.6 ± 7.5111.0 ± 10.4/61.3 ± 7.9Proteinuria (g/day)0.07 ± 0.040.37 ± 0.26\*Hematuria index0.93 ± 0.371.89 ± 0.70\*Serum creatine (mg/dl)0.54 ± 0.140.54 ± 0.1524-h creatine clearance (ml/min per 1.73 m^2^)100.5 ± 23.5103.8 ± 29.9*MGA* minor glomerular abnormalities,*IgAN* immunoglobulin A nephropathyData are means ± standard deviation\**P* \< 0.01 vs MGA

Histological scoring of glomerular cell proliferation, glomerulosclerosis, and tubulointerstitial changes {#Sec4}
---------------------------------------------------------------------------------------------------------

For light-microscopic examination, the biopsied tissues were fixed in 10% buffered formalin and embedded in paraffin. Paraffin sections (3 μm) were stained with periodic acid-Schiff reagent. All glomeruli in each section (usually 10--26) were coded and read by a blinded observer. The number of cells in at least four equatorially cut glomeruli in each section was counted, and the average number of cells was used as an indicator of glomerular cell proliferation, as previously described \[[@CR25]\]. The glomerulosclerosis (GS) score was determined using a previously described method with a modification \[[@CR26]\]. The percentage of each glomerulus occupied by mesangial ECM was estimated and assigned a code as follows: 0, absent; 1+, 1--5%; 2+, 5--25%; 3+, 25--50%; 4+, \>50%; and the mean value per specimen was calculated \[[@CR27]\]. To evaluate the level of tubulointerstitial change, three to five fields of the cortical interstitium in each section were examined, as previously described \[[@CR28]\]. In each field, tubulointerstitial change, like tubular atrophy and interstitial broadening, were graded as follows: 0, representing involvement of \<5%; 1+, involvement between 5 and 20%; 2+, involvement between 20 and 40%; 3+, involvement of \>40%.

Antibodies {#Sec5}
----------

Chicken IgY-rich fraction against highly purified full-length human plasma AGT (anti-AGT antibody) was used for immunohistochemistry \[[@CR29]\]. Mouse monoclonal anti-ACE antibody, rabbit polyclonal anti-ang II serum, and rabbit polyclonal anti-AT1R antibody were purchased from Chemicon International (Temecula, CA, USA), IgG corporation (Nashville, TN, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Mouse monoclonal anti-α-smooth-muscle (α-SM) actin antibody (1A4) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and was used to detect activated human MC. Rabbit polyclonal anti-TGF-β antibody was a kind gift from Dr. Kawachi (Niigata University, Niigata, Japan).

Immunohistochemistry {#Sec6}
--------------------

The glomerular expression of AGT or AT1R was detected by an immunoperoxidase technique, as previously described \[[@CR27]\]. Briefly, the sections (3 μm) were incubated with the primary antibodies overnight at 4°C. After rinsing, the sections were incubated with either biotinylated anti-chicken IgG (for AGT) (Vector Labs, Burlingame, CA, USA) or biotinylated anti-rabbit IgG (for AT1R) (Vector Labs). After rinsing, the sections were incubated with avidin-biotin-peroxidase complex (ABC Elite; Vector Labs), followed by 3,3′-diaminobenzidine (Dojindo, Kumamoto, Japan). Each section was counterstained with Mayer's hematoxylin (Wako, Tokyo, Japan), dehydrated, and coverslipped.

In double-staining experiments, 3-μm frozen sections stained with chicken anti-AGT antibody, and fluorescein-isothiocyanate (FITC)-labeled donkey anti-chicken IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) were further incubated with either mouse anti-CD31 antibody (DAKO, Glostrup, Denmark), mouse monoclonal anti-α-SM actin antibody (1A4), or mouse monoclonal synaptopodin antibody (G1D4; Progen Biotechnik, Heidelberg, Germany), followed by an appropriate tetramethylrhodamine-isothiocyanate (TRITC)-coupled donkey anti-mouse antibody (Jackson Immuno-Research Laboratories). Indirect immunofluorescent staining was performed using the following primary antibodies: anti-ACE antibody, anti-ang II antiserum, anti-α-SM actin antibody, and anti-TGF-β antibody. FITC-labeled donkey anti-rabbit IgG antibody, donkey anti-mouse IgG, and TRITC-labeled donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories) were used as the secondary antibodies. Frozen sections were incubated with primary antibodies for 1 h, and then secondary antibodies, appropriately. To evaluate the level of glomerular staining with each antibody, we performed semiquantitative analysis. The immunostaining of AGT was graded as follows: 0, very weak or absent capillary or mesangial staining; 1+, weak capillary staining with 1--25% focally increased capillary staining; 2+, 25--50% of glomerular tuft demonstrating strong capillary and mesangial staining; 3+, 50--75% of glomerular tuft demonstrating strong capillary and mesangial staining; 4+, 75% or more of the glomerular tuft demonstrated strong capillary and mesangial staining, as previously described \[[@CR25]\]. The immunostaining of ACE, ang II, AT1R, TGF-β, and α-SM actin was graded as follows: 0, no staining; 1+, weak staining; 2+, mild staining; 3+, moderate staining; 4+, marked staining. At least four equatorially sectioned glomeruli in each section were evaluated blindly by two separate investigators. The individual immunostaining score was determined by calculating the average value per single glomerulus \[[@CR27]\].

Cell culture {#Sec7}
------------

Cultured human GEC derived from normal human kidneys were purchased from Cell System (Kirkland, WA, USA). Human GEC were cultured on culture flask coated with type 1 collagen, as described previously \[[@CR30]\]. Human GEC were used at the sixth to eighth passage in our experiments. At about 70--80% confluency, GEC growth was arrested by incubation for 48 h in serum-free medium and then treated with ang II at increasing concentrations (0, 10^−11^, 10^−9^, 10^−7^ M) for 3--12 h to detect mRNA or protein, respectively. In addition, a time-course study was undertaken to assess changes in AGT mRNA expression at 0, 1, 3, 6, 12, and 24 h and protein expression at 0, 6, 12, and 24 h with 10^−7^ M ang II-treated GEC. Cells were harvested for RNA extraction and total cell extract preparation.

Western blot {#Sec8}
------------

Human GEC cultures were dissolved in radioimmunoprecipitation assay (RIPA) buffer. Protein samples (25 μg) were separated by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes (Amersham Bioscience, Piscataway, NJ, USA). The membranes were probed with anti-AGT antibody (1:1,000) and then incubated with a horseradish peroxidase-conjugated rabbit anti-chicken/turkey IgG (H+L) (1:2,000; Zymed Laboratories, San Francisco, CA, USA). Equivalent protein loading for each lane was confirmed by stripping and reblotting each membrane for β-actin (1:10,000; Sigma-Aldrich). Immunoreactive proteins were detected with an enhanced chemiluminescence detection system (Amersham Corp., Arlington Heights, IL, USA). The antibodies were tested on human purified AGT (Calbiochem, Merck, Darmstadt, Germany) as control, where two bands between 50 and 60 kD were detected \[[@CR31]\]. Bands were quantitated by ImageJ 1.33u (National Institute of Health), and the fold expression was indicated as the relative protein level.

RT-PCR {#Sec9}
------

Total RNA (500 ng) extracted from human cell cultures was reverse transcripted using the SYBR ExScript RT-PCR Kit (TaKaRa, Kyoto, Japan). The complementary DNAs (cDNAs) were amplified by RT-PCR with primers for human AGT (forward 5′-TCTCCCCGGACCATCCA-3′ and reverse 5′-TGCTCAATTTTTGCAGGTTCAG-3′) and glyceraldehyde-3 phosphate dehydrogenase (G3PDH) (forward 5′-GAAGGTGAAGGTCGGAGT-3′ and reverse 5′-TGGCAACAATATCCACTTTACCA-3′) as an internal control, using iCycler Thermal Cycler (BioRad, Hercules, CA, USA) \[[@CR17], [@CR32]\]. Melting curve analysis and PAGE confirmed the specificity of the amplification products. Semiquantification data were analyzed with iCycler analysis software and expressed as the ratio between starting the quantity mean of the target and the*G3PDH* gene.

Statistical analysis {#Sec10}
--------------------

Results are presented as means ± standard deviation (SD). StatView (SAS institute) was used for statistical analyses. Between-group differences were assessed by the unpaired *t* test. The correlation of two variations was evaluated using Pearson's or Spearman's correlation coefficients. Western blot and RT-PCR analyses were performed at least three times, and representative results are shown in the figures. The mRNA expression or protein synthesis of AGT in cultured cells was analyzed by*t* test. Values of*P* \< 0.05 were considered statistically significant.

Results {#Sec11}
=======

Clinical data and histologic changes in patients {#Sec12}
------------------------------------------------

Clinical data in patients with MGA or IgAN are listed in Table [1](#Tab1){ref-type="table"}. There were no significant differences between MGA and IgAN patients for age, follow-up term from onset of urinary abnormalities, blood pressure, serum creatinine, and creatinine clearance at the time of biopsy. Mean urine protein excretion was significantly higher in IgAN patients than that in MGA patients (*P* \< 0.01). The extent of glomerular cellularity, ECM accumulation, and tubulointerstitial changes were semiquantified in both patient groups and are shown in Fig. [1](#Fig1){ref-type="fig"}. The glomerular cell number and GS score were significantly higher in IgAN patients compared with those in MGA patients (MGA vs IgAN; mean cell number: 66.1 vs 77.9,*P* \< 0.05; mean GS score: 0.73 vs 1.58,*P* \< 0.01). Tubular atrophy and interstitial broadening were faintly present in IgAN patients but not in MGA patients. However, there was no significant difference in tubulointerstitial score change between the two groups (mean score: 0.00 in MGA vs 0.26 in IgAN,*P* = 0.188). Fig. 1The scorings of glomerular cell number (**a**), glomerulosclerosis (**b**), and tubulointerstitial changes (**c**) in the biopsies. Glomerular cell count and glomerulosclerotic indexes except tubulointerstitial changes significantly increased in immunoglobulin A nephropathy (IgAN) (■) compared with minor glomerular abnormalities (MGA) (□). \**P* \< 0.05 vs MGA; †*P* \< 0.01 vs MGA

Expression of RAS components, TGF-β, and α-SM actin in patients with MGA or IgAN {#Sec13}
--------------------------------------------------------------------------------

The glomerular localization of RAS components was studied by immunohistochemistry in renal biopsies from patients with either IgAN or MGA. Immunostaining of AGT was detected mainly in proximal tubules and weakly in GEC lining capillary walls in MGA specimens, as in normal tissues (Fig. [2](#Fig2){ref-type="fig"}a). This renal localization of AGT was consistent with rat renal localization of AGT, as previously described \[[@CR33]\]. Of note, the staining level of AGT was enhanced in a typical endocapillary pattern, including changes of GEC and MC in IgAN patients (Fig. [2](#Fig2){ref-type="fig"}b). No positive immunostaining of AGT was seen when a chicken antibody against AGT, absorbed by preincubation with excess human purified AGT, was used as the primary antibody or when the primary antibody was omitted (Fig. [2](#Fig2){ref-type="fig"}c). The double immunostaining in IgAN showed that AGT was primarily detected on GEC, to a lesser extent on MC, and only faintly on podocytes, supporting the glomerular localization of AGT in an immunoperoxidase technique (Fig. [2](#Fig2){ref-type="fig"}d--l). Fig. 2Glomerular expression of angiotensinogen (AGT) and its localization in the biopsies. Kidney sections were immunostained with anti-AGT antibody in patients with minor glomerular abnormalities (MGA) (**a**) or immunoglobulin A nephropathy (IgAN) (**b**) (original magnification ×200). Positive immunostaining of AGT could not be detected when a chicken antibody against AGT, absorbed by preincubation with excess human purified AGT, was used as the primary antibody (**c**). To identify glomerular localization of AGT, double immunofluorescence staining of AGT (*green*; **d**, **g**, **j**) with either glomerular endothelial cells (GEC) marker CD31 (*red*; **e**), activated mesangial cells (MC) (*red*; **h**), or podocyte marker (*red*; **k**) in IgAN was performed. Merged images show that AGT clearly colocalized on GEC (**f**), weakly on activated MC (**i**), and only faintly on podocyte (**l**) in IgAN (×400)

ACE and ang II expression were examined by immunofluorescence, as specific staining was not detected by the immunoperoxidase technique. Faint immunofluorescence of ACE and ang II was observed in glomeruli from patients with MGA, as in normal tissues (Fig. [3](#Fig3){ref-type="fig"}a,c). In IgAN patients, staining for ACE tended to increase in an endocapillary pattern, but that of ang II was enhanced in GEC and MC of nephritic glomeruli (Fig. [3](#Fig3){ref-type="fig"}b,d). A similar staining level of AT1R was found in glomeruli, particularly MC, in specimens from patients with MGA or IgAN, and in control kidney tissues (Fig. [3](#Fig3){ref-type="fig"}e,f). Fig. 3Glomerular expression of components of the renin-angiotensin system (RAS) in the biopsies. Kidney sections were immunostained with either anti-angiotensin-converting enzyme antibody (**a**, **b**), anti-angiotensin II antibody (**c**, **d**) or anti-angiotensin II type 1 receptor antibody (**e**, **f**) in patients with minor glomerular abnormalities (MGA) (**a**, **c**, **e**) or immunoglobulin A nephropathy (IgAN) (**b**, **d**, **f**) (original magnification, ×200)

A semiquantitative analysis of glomerular staining for AGT, ACE, ang II, and AT1R revealed that the level of glomerular AGT (mean score 1.89) and ang II (mean score 2.09) but not ACE (mean score 0.96) was significantly enhanced in the IgAN group compared with the MGA group (mean scores for AGT, ang II, ACE 0.93, 1.00, 0.50, respectively) (*P* \< 0.01) (Fig. [4](#Fig4){ref-type="fig"}). The expression level of AT1R tended to be lower, but not statistically significant, in patients with IgAN compared with the MGA group (mean score 1.63 in MGA vs 1.26 in IgAN). Fig. 4Semiquantitative assessment of immunostaining of angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II (ang II) and ang II type 1 receptor (AT1R) in the kidney sections from patients with minor glomerular abnormalities (MGA) (□) or immunoglobulin A nephropathy (IgAN) (■). Data are means ± standard deviation. †*P* \< 0.01 vs MGA

The expression of TGF-β and α-SM actin, potential factors associated with GN progression, was greatly enhanced in the expanded mesangial regions in patients with IgAN in contrast with patients with MGA (Fig. [5](#Fig5){ref-type="fig"}a--d). Semiquantitative analysis indicated that the levels of TGF-β and α-SM actin expression were significantly higher in the IgAN group than in the MGA group (mean score 0.50 and 0.63 in MGA vs 1.91 and 1.91 in IgAN;*P* \< 0.01) (Fig. [5](#Fig5){ref-type="fig"}e). Fig. 5Glomerular expression of transforming growth factor-β (TGF-β) and α-smooth-muscle (α-SM) actin in biopsies. Kidney sections were immunostained with either anti-TGF-β antibody (**a**, **b**) or α-SM actin (**c**, **d**) in patients with minor glomerular abnormalities (MGA) (**a**, **c**) or immunoglobulin A nephropathy (IgAN) (**b**, **d**) (original magnification ×200). Semiquantitative assessment of immunofluorescence staining of TGF-β and α-SM actin immunostaining in patients with MGA (□) or IgAN (■). †*P* \< 0.01vs MGA

Correlation of RAS components with pathologic changes in patients with MGA or IgAN {#Sec14}
----------------------------------------------------------------------------------

Possible relationships between glomerular RAS activation and injury in diseased kidney were investigated to examine the correlations between the expression of RAS components, ang II-inducible factors, TGF-β and α-SM actin histologic findings, and urinary findings (proteinuria and hematuria) in patients with MGA or IgAN (Fig. [6](#Fig6){ref-type="fig"}). The glomerular AGT expression was positively correlated with ang II (*r* = +0.711,*P* \< 0.001) (Fig. [6](#Fig6){ref-type="fig"}a), TGF-β (*r* = +0.723,*P* \< 0.001) (Fig. [6](#Fig6){ref-type="fig"}b), α-SM actin (*r* = +0.565,*P* \< 0.005) (Fig. [6](#Fig6){ref-type="fig"}c), glomerular cell number (*r* = +0.542,*P* \< 0.005) (Fig. [6](#Fig6){ref-type="fig"}d), GS score (*r* = +0.768,*P* \< 0.001) (Fig. [6](#Fig6){ref-type="fig"}e), and proteinuria (*r* = +0.436,*P* \< 0.05) (Fig. [6](#Fig6){ref-type="fig"}f). Similarly, glomerular ang II level showed a significant positive correlation with that of TGF-β (*r* = +0.782,*P* \< 0.001) (Fig. [6](#Fig6){ref-type="fig"}g), α-SM actin (*r* = +0.640,*P* \< 0.001) (Fig. [6](#Fig6){ref-type="fig"}h), cell number (*r* = +0.441,*P* \< 0.05) (Fig. [6](#Fig6){ref-type="fig"}i), GS score (*r* = 0.826,*P* \< 0.001) (Fig. [6](#Fig6){ref-type="fig"}j), and proteinuria (*r* = +0.364,*P* \< 0.05) (Fig. [6](#Fig6){ref-type="fig"}k). However, neither AGT nor ang II showed a significant correlation with expression of ACE, AT1R, and hematuria index. Finally, a positive correlation was demonstrated between TGF-β and α-SM actin (*r* = +0.625,*P* \< 0.001) (Fig. [6](#Fig6){ref-type="fig"}l). Fig. 6Plots of correlations between the staining levels of angiotensinogen (AGT) and angiotensin II (ang II) (**a**), AGT and transforming growth factor-β (TGF-β) (**b**), AGT and α-smooth-muscle (α-SM) actin (**c**), AGT and glomerular cell number (cell number) (**d**), AGT and glomerulosclerosis (GS) score (**e**), AGT and proteinuria (**f**), ang II and TGF-β (**g**), ang II and α-SM actin (**h**), ang II and cell number (**i**), ang II and GS score (**j**), ang II and proteinuria (**k**), and TGF-β and α-SM actin (**l**) in patients with minor glomerular abnormalities (MGA) (○) or immunoglobulin A nephropathy (IgAN) (•) (correlation;*P* value) The levels of AGT positively correlate with the level of ang II (*r* = +0.711;*P* \< 0.001), TGF-β (*r* = +0.723;*P* \< 0.001), cell number (*r* = +0.542;*P* \< 0.005), GS score (*r* = +0.768;*P* \< 0.001), and proteinuria (*r* = +0.436; *P* \< 0.05). Ang II is also positively correlated with TGF-β (*r* = +0.782; *P* \< 0.001), α-SM actin (*r* = +0.640;*P* \< 0.001), cell number (*r* = +0.441;*P* \< 0.05), GS score (*r* = +0.826;*P* \< 0.001), and proteinuria (*r* = +0.364;*P* \< 0.05). The levels of TGF-β positively correlate with the level of α-SM actin (*r* = +0.625;*P* \< 0.001)

Effect of ang II on the AGT mRNA and protein levels by human GEC {#Sec15}
----------------------------------------------------------------

The regulation of AGT expression by GEC and a possible role of GEC-AGT in disease progression of IgAN were examined using cultured human GEC. The addition of 10^−7^ M ang II rapidly induced AGT mRNA expression of quiescent human GEC after stimulation for 1 h. This increase peaked at 3 h, with a sevenfold increase, and then gradually decreased during the course of the experiment (Fig. [7](#Fig7){ref-type="fig"}a). When the response of AGT transcript to ang II dose was investigated after incubation for 3 h, a dose-dependent increase between 10^−11^ and 10^−7^ M was seen (Fig. [7](#Fig7){ref-type="fig"}b). Western blot analysis revealed a time-dependent increase of AGT protein product to 10^−7^ M ang II stimulation. The increased expression of AGT protein followed the increase of AGT mRNA by GEC and peaked at 12 and 24 h after stimulation (Fig. [8](#Fig8){ref-type="fig"}a). Consistent with the results of RT-PCR analysis, a dose-dependent increase of human GEC-AGT protein to ang II stimulation was observed between 10^−11^ M and 10^−7^ M (Fig. [8](#Fig8){ref-type="fig"}b). Fig. 7Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) messenger ribonucleic acid (mRNA) by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10^−7^ M ang II for the indicated time, extracted, and analyzed for AGT mRNA levels by real-time polymerase chain reaction (RT-PCR) (**a**). Values are means ± standard deviation (SD). \**P* \< 0.05 and †*P* \< 0.01 vs time 0. Human GEC were incubated for 3 h with vehicle control or with indicated doses of ang II, extracted, and analyzed for AGT mRNA levels by RT-PCR (**b**). The*graph* represents the mean ± SD of at least three independent experiments. \**P* \< 0.05 and †*P* \< 0.01 vs controlFig. 8Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) protein by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10^−7^ M ang II for the indicated time, extracted, and then subjected to Western blot analysis for AGT and β-actin (**a**). Western blot analysis demonstrated two specific immunoreactive bands between 50 and 60 kD. Data for AGT protein levels were normalized by β-actin protein levels. The*graph* represents the mean ± standard deviation (SD) of at least three independent experiments. †*P* \< 0.01 vs time 0. Human GEC were incubated for 12 h with vehicle control or with indicated doses of ang II, extracted, and analyzed, as described in **a** (**b**). Data are means ± SD of at least three independent experiments. \**P* \< 0.05 vs control

Discussion {#Sec16}
==========

Enhanced intrarenal RAS has been implicated in the development of hypertension and the progression of chronic renal diseases, including IgAN \[[@CR1], [@CR2], [@CR17]\]. Ang II, the major effector molecule of the RAS cascade, is a key mediator of glomerular hypertension as well as glomerular sclerosis through the induction of TGF-β \[[@CR5], [@CR6]\]. However, glomerular expression of RAS components and their association with local RAS activity and injury has not been extensively studied in human subjects, especially pediatric patients with IgAN.

In this study, we demonstrated for the first time that both glomerular expression of AGT protein, a sole substrate for RAS cascade, and ang II were strikingly increased with GEC and MC in nephritic glomeruli of pediatric IgAN. As it is already known that ang II is locally produced within the glomerulus and RAS is present in glomerular cell types such as GEC, MC, and podocyte \[[@CR19], [@CR20], [@CR34]\], the increased expression of ang II seen in pediatric IgAN most likely reflects enhanced glomerular RAS activation under this disease setting.

We also demonstrated that there was a positive correlation between levels of glomerular AGT, ang II, and ang II-inducible factors (TGF-β and α-SM actin) and glomerular injury (cell proliferation and ECM accumulation), suggesting that the activated glomerular RAS cascade contributes to the development and progression of glomerular injury in pediatric IgAN. There are several studies investigating glomerular gene expression of RAS components in IgAN \[[@CR17], [@CR24], [@CR35], [@CR36]\]. Most studies have shown an increased expression of renin,*AGT*, and*ACE* genes and decreased expression of*AT1R* gene in nephritic glomeruli of IgAN. Furthermore, it has been shown that a negative feedback loop exists between ang II and its receptor, AT1R, in glomerular cells \[[@CR36]\]. Therefore, if there was a proportional increase in ang II as a result of increased upstream components of RAS, a proportional deactivation of*AT1R* expression in IgAN would be expected. Here, we found a significantly greater expression of glomerular AGT protein and ang II peptides and a tendency for higher ACE protein levels and lower AT1R protein levels in pediatric IgAN compared with MGA patients, indicating that the glomerular AGT level may directly regulate the ang II activity under the coordination of ACE and AT1R expression and other ang II-producible enzyme activity. Various enzymes, including cathepsin and chymase, are involved in the RAS besides renin and ACE, which are classical enzyme synthesizing ang II from AGT \[[@CR37]\]. Indeed, approximately 40% of the ang II found in the kidney is generated by ACE-independent pathways \[[@CR38]\]. In any case, local levels of renin and ACE are not related to the synthesis of angII in situations where AGT levels are very high \[[@CR18], [@CR20], [@CR21]\]. Thus, the quantity of AGT might well be the most important element for the level of ang II production. Indeed, recent experimental studies using rat models of nephropathy indicated that enhanced intrarenal AGT expression is linked to the increased level of ang II production and contributes to the development of glomerular injury \[[@CR20]--[@CR22], [@CR39]\].

We previously disclosed the mechanisms and the role of ang II-induced ECM deposition through MC \[[@CR5], [@CR6]\]. Ang II stimulates ECM synthesis through he induction of TGF-β expression in cultured rat MC \[[@CR5]\] and affects the plasminogen activator/plasminogen activator inhibitor-1 system to result in accelerated deposition of ECM \[[@CR6]\], which indicates that ang II can act as a potent fibrotic molecule independent of its effects on blood pressure. Ang II can also induce MC activation (α-SM actin positive) \[[@CR39]--[@CR42]\]. In addition, experimental and human studies have shown that the degree of mesangial cellularity is associated with a high sensitivity to beneficial effects of ACEi and ARB on glomerular structure and proteinuria, suggesting that the glomerular ang II level may contribute to proliferation of MC \[[@CR43]\]. Thus, our findings obtained here that the level of glomerular ang II is associated with the levels of TGF-β and α-SM actin expression as well as glomerular injury characterized by cell proliferation and ECM accumulation are consistent with the recent view of ang II action.

GEC damage and dysfunction are early features of many types of GN \[[@CR44], [@CR45]\]. Injury to GEC induces the secretion of various mediators, such as vasoactive substances, cytokines, and growth factors critical in the regulation of glomerular capillary tone and glomerular remodeling \[[@CR19], [@CR46]--[@CR48]\]. Lee et al. demonstrated that GEC injury results in increased AGT and TGF-β mRNA by GEC and MC in the subtotal nephrectomized rat model, suggesting that activated or injured endothelial cells synthesize AGT, triggering a cascade of ang II, TGF-β, and ECM protein gene expression with resultant development of the glomerular sclerotic lesion \[[@CR19]\]. Here we provide in vivo data showing a striking increase of GEC-AGT and ang II in patients with IgAN as well as in vitro data indicating the potential of GEC to synthesize AGT protein and stimulatory effects of ang II on GEC-AGT expression. Taken together, it seems likely that GEC plays a crucial role in the activation of local RAS, and self-amplifying properties of ang II production in GEC are associated with the glomerular hemodynamic changes and the development of progressive glomerular injury in human GN.

In general, RAS inhibitors are commonly used by chronic IgAN patients with hypertension or those with heavy proteinuria or initial impairment of renal function. We should stress that glomerular RAS activation could occur in pediatric IgAN without heavy proteinuria, hypertension, and renal impairment. IgAN patients in this study had a short-term observation period from onset to time of renal biopsy, renal lesions, characterized with mesangial proliferative changes, low-grade interstitial fibrosis, and tubular atrophy, indicating that they were diagnosed at an early stage of IgAN \[[@CR14], [@CR49]\]. Thus, considering the accumulating evidence that ang II plays a critical role in MC activation as well as glomerular hemodynamic changes and development of glomerulosclerosis, early treatment with ACEi and/or ARB in pediatric IgAN, even in the absence of hypertension and/or severe proteinuria, is reasonable for preventing progression in IgAN.

In conclusion, our study showed that activated glomerular AGT expression is likely to be involved in local RAS activation, leading to enhanced local ang II production, in pediatric IgAN with normal blood pressure and normal renal function and, thereby, may trigger a dangerous RAS cascade resulting in overproduction of TGF-β and progression of glomerular injury. Moreover, a self-amplification loop of GEC-AGT production with ang II stimulation seems to drive the further injury of nephritic glomeruli in IgAN patients. These data provide a rationale for early intervention with RAS inhibitors in pediatric IgAN patients even in the absence of hypertension and/or impairment of renal function to prevent progression of glomerular injury.
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